speb/financial-data huggingface dataset:
NEPHROPLUS.NS income_statement (quarterly, 2026-03-31) — Net Income Continuous Operations: 303700000.00
NEPHROPLUS.NS income_statement (annual, 2026-03-31) — Net Income From Continuing And Discontinued Operation: 768400000.00
NEPHROPLUS.NS income_statement (quarterly, 2026-03-31) — Net Income From Continuing And Discontinued Operation: 303700000.00
NEPHROPLUS.NS income_statement (annual, 2026-03-31) — Net Income From Continuing Operation Net Minority Interest: 768400000.00
NEPHROPLUS.NS income_statement (quarterly, 2026-03-31) — Net Income From Continuing Operation Net Minority Interest: 303700000.00
NEPHROPLUS.NS cash_flow (annual, 2026-03-31) — Net Income From Continuing Operations: 974740000.00
NEPHROPLUS.NS income_statement (annual, 2026-03-31) — Net Income Including Noncontrolling Interests: 768400000.00
NEPHROPLUS.NS income_statement (quarterly, 2026-03-31) — Net Income Including Noncontrolling Interests: 303700000.00
NEPHROPLUS.NS cash_flow (annual, 2026-03-31) — Net Intangibles Purchase And Sale: -4260000.00
NEPHROPLUS.NS income_statement (annual, 2026-03-31) — Net Interest Income: -505350000.00
NEPHROPLUS.NS income_statement (quarterly, 2026-03-31) — Net Interest Income: -31800000.00
NEPHROPLUS.NS cash_flow (annual, 2026-03-31) — Net Investment Purchase And Sale: -1453890000.00
NEPHROPLUS.NS cash_flow (annual, 2026-03-31) — Net Issuance Payments Of Debt: -2027930000.00
NEPHROPLUS.NS cash_flow (annual, 2026-03-31) — Net Long Term Debt Issuance: -1149070000.00
NEPHROPLUS.NS income_statement (annual, 2026-03-31) — Net Non Operating Interest Income Expense: -505350000.00
NEPHROPLUS.NS income_statement (quarterly, 2026-03-31) — Net Non Operating Interest Income Expense: -31800000.00
NEPHROPLUS.NS cash_flow (annual, 2026-03-31) — Net Other Investing Changes: -993180000.00
NEPHROPLUS.NS balance_sheet (annual, 2026-03-31) — Net PPE: 4146620000.00
NEPHROPLUS.NS balance_sheet (quarterly, 2026-03-31) — Net PPE: 4146620000.00
NEPHROPLUS.NS cash_flow (annual, 2026-03-31) — Net PPE Purchase And Sale: -1187140000.00
NEPHROPLUS.NS cash_flow (annual, 2026-03-31) — Net Short Term Debt Issuance: -878860000.00
NEPHROPLUS.NS balance_sheet (annual, 2026-03-31) — Net Tangible Assets: 9959340000.00
NEPHROPLUS.NS balance_sheet (quarterly, 2026-03-31) — Net Tangible Assets: 9959340000.00
NEPHROPLUS.NS balance_sheet (annual, 2026-03-31) — Non Current Deferred Taxes Assets: 339610000.00
NEPHROPLUS.NS balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Taxes Assets: 339610000.00
NEPHROPLUS.NS balance_sheet (annual, 2026-03-31) — Non Current Deferred Taxes Liabilities: 35480000.00
NEPHROPLUS.NS balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Taxes Liabilities: 35480000.00
NEPHROPLUS.NS balance_sheet (annual, 2026-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 58570000.00
NEPHROPLUS.NS balance_sheet (quarterly, 2026-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 58570000.00
NEPHROPLUS.NS balance_sheet (annual, 2026-03-31) — Non Current Prepaid Assets: 53960000.00
NEPHROPLUS.NS balance_sheet (quarterly, 2026-03-31) — Non Current Prepaid Assets: 53960000.00
NEPHROPLUS.NS income_statement (annual, 2026-03-31) — Normalized EBITDA: 2384420000.00
NEPHROPLUS.NS income_statement (quarterly, 2026-03-31) — Normalized EBITDA: 622440000.00
NEPHROPLUS.NS income_statement (annual, 2026-03-31) — Normalized Income: 717293682.42
NEPHROPLUS.NS income_statement (quarterly, 2026-03-31) — Normalized Income: 303700000.00
NEPHROPLUS.NS cash_flow (annual, 2026-03-31) — Operating Cash Flow: 2325790000.00
NEPHROPLUS.NS income_statement (annual, 2026-03-31) — Operating Income: 1389480000.00
NEPHROPLUS.NS income_statement (quarterly, 2026-03-31) — Operating Income: 279230000.00
NEPHROPLUS.NS income_statement (annual, 2026-03-31) — Operating Revenue: 9944680000.00
NEPHROPLUS.NS income_statement (quarterly, 2026-03-31) — Operating Revenue: 2656150000.00
NEPHROPLUS.NS balance_sheet (annual, 2026-03-31) — Ordinary Shares Number: 100340717.00
NEPHROPLUS.NS balance_sheet (quarterly, 2026-03-31) — Ordinary Shares Number: 100340717.00
NEPHROPLUS.NS balance_sheet (annual, 2026-03-31) — Other Current Assets: 22820000.00
NEPHROPLUS.NS balance_sheet (quarterly, 2026-03-31) — Other Current Assets: 22820000.00
NEPHROPLUS.NS balance_sheet (annual, 2026-03-31) — Other Current Liabilities: 370340000.00
NEPHROPLUS.NS balance_sheet (quarterly, 2026-03-31) — Other Current Liabilities: 370340000.00
NEPHROPLUS.NS balance_sheet (annual, 2026-03-31) — Other Equity Interest: 180000000.00
NEPHROPLUS.NS balance_sheet (quarterly, 2026-03-31) — Other Equity Interest: 180000000.00
NEPHROPLUS.NS balance_sheet (annual, 2026-03-31) — Other Intangible Assets: 338660000.00
NEPHROPLUS.NS balance_sheet (quarterly, 2026-03-31) — Other Intangible Assets: 338660000.00
NEPHROPLUS.NS balance_sheet (annual, 2026-03-31) — Other Investments: 71430000.00
NEPHROPLUS.NS balance_sheet (quarterly, 2026-03-31) — Other Investments: 71430000.00
NEPHROPLUS.NS cash_flow (annual, 2026-03-31) — Other Non Cash Items: 491710000.00
NEPHROPLUS.NS balance_sheet (annual, 2026-03-31) — Other Non Current Assets: -20000.00
NEPHROPLUS.NS balance_sheet (quarterly, 2026-03-31) — Other Non Current Assets: -20000.00
NEPHROPLUS.NS balance_sheet (annual, 2026-03-31) — Other Non Current Liabilities: -1070000.00
NEPHROPLUS.NS balance_sheet (quarterly, 2026-03-31) — Other Non Current Liabilities: -1070000.00
NEPHROPLUS.NS income_statement (annual, 2026-03-31) — Other Non Operating Income Expenses: 32250000.00
NEPHROPLUS.NS income_statement (quarterly, 2026-03-31) — Other Non Operating Income Expenses: 115690000.00
NEPHROPLUS.NS income_statement (annual, 2026-03-31) — Other Operating Expenses: 1337270000.00
NEPHROPLUS.NS income_statement (quarterly, 2026-03-31) — Other Operating Expenses: 557620000.00
NEPHROPLUS.NS balance_sheet (annual, 2026-03-31) — Other Payable: 285420000.00
NEPHROPLUS.NS balance_sheet (quarterly, 2026-03-31) — Other Payable: 285420000.00
NEPHROPLUS.NS balance_sheet (annual, 2026-03-31) — Other Properties: 3961940000.00
NEPHROPLUS.NS balance_sheet (quarterly, 2026-03-31) — Other Properties: 3961940000.00
NEPHROPLUS.NS balance_sheet (annual, 2026-03-31) — Other Short Term Investments: 3328110000.00
NEPHROPLUS.NS balance_sheet (quarterly, 2026-03-31) — Other Short Term Investments: 3328110000.00
NEPHROPLUS.NS income_statement (annual, 2026-03-31) — Other Special Charges: -14210000.00
NEPHROPLUS.NS income_statement (annual, 2026-03-31) — Otherunder Preferred Stock Dividend: 0.00
NEPHROPLUS.NS income_statement (quarterly, 2026-03-31) — Otherunder Preferred Stock Dividend: 0.00
NEPHROPLUS.NS balance_sheet (annual, 2026-03-31) — Payables: 1882010000.00
NEPHROPLUS.NS balance_sheet (quarterly, 2026-03-31) — Payables: 1882010000.00
NEPHROPLUS.NS balance_sheet (annual, 2026-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 24370000.00
NEPHROPLUS.NS balance_sheet (quarterly, 2026-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 24370000.00
NEPHROPLUS.NS balance_sheet (annual, 2026-03-31) — Prepaid Assets: 290280000.00
NEPHROPLUS.NS balance_sheet (quarterly, 2026-03-31) — Prepaid Assets: 290280000.00
NEPHROPLUS.NS income_statement (annual, 2026-03-31) — Pretax Income: 974740000.00
NEPHROPLUS.NS income_statement (quarterly, 2026-03-31) — Pretax Income: 332190000.00
NEPHROPLUS.NS balance_sheet (annual, 2026-03-31) — Properties: 0.00
NEPHROPLUS.NS balance_sheet (quarterly, 2026-03-31) — Properties: 0.00
NEPHROPLUS.NS cash_flow (annual, 2026-03-31) — Provisionand Write Offof Assets: 237740000.00
NEPHROPLUS.NS cash_flow (annual, 2026-03-31) — Purchase Of Business: -545790000.00
NEPHROPLUS.NS cash_flow (annual, 2026-03-31) — Purchase Of Intangibles: -4260000.00
NEPHROPLUS.NS cash_flow (annual, 2026-03-31) — Purchase Of Investment: -3525800000.00
NEPHROPLUS.NS cash_flow (annual, 2026-03-31) — Purchase Of PPE: -1189360000.00
NEPHROPLUS.NS income_statement (annual, 2026-03-31) — Reconciled Cost Of Revenue: 4189330000.00
NEPHROPLUS.NS income_statement (quarterly, 2026-03-31) — Reconciled Cost Of Revenue: 1101570000.00
NEPHROPLUS.NS income_statement (annual, 2026-03-31) — Reconciled Depreciation: 894850000.00
NEPHROPLUS.NS income_statement (quarterly, 2026-03-31) — Reconciled Depreciation: 258450000.00
NEPHROPLUS.NS income_statement (annual, 2026-03-31) — Rent And Landing Fees: 40350000.00
NEPHROPLUS.NS income_statement (annual, 2026-03-31) — Rent Expense Supplemental: 40350000.00
NEPHROPLUS.NS cash_flow (annual, 2026-03-31) — Repayment Of Debt: -1149070000.00
NEPHROPLUS.NS balance_sheet (annual, 2026-03-31) — Restricted Cash: 12300000.00
NEPHROPLUS.NS balance_sheet (quarterly, 2026-03-31) — Restricted Cash: 12300000.00
NEPHROPLUS.NS balance_sheet (annual, 2026-03-31) — Retained Earnings: 472340000.00
NEPHROPLUS.NS balance_sheet (quarterly, 2026-03-31) — Retained Earnings: 472340000.00
NEPHROPLUS.NS cash_flow (annual, 2026-03-31) — Sale Of Investment: 2071910000.00
NEPHROPLUS.NS cash_flow (annual, 2026-03-31) — Sale Of PPE: 2220000.00
NEPHROPLUS.NS income_statement (annual, 2026-03-31) — Selling And Marketing Expense: 115680000.00
NEPHROPLUS.NS income_statement (annual, 2026-03-31) — Selling General And Administration: 419280000.00
NEPHROPLUS.NS balance_sheet (annual, 2026-03-31) — Share Issued: 100340717.00
NEPHROPLUS.NS balance_sheet (quarterly, 2026-03-31) — Share Issued: 100340717.00
NEPHROPLUS.NS income_statement (annual, 2026-03-31) — Special Income Charges: 450000.00
NEPHROPLUS.NS cash_flow (annual, 2026-03-31) — Stock Based Compensation: 91830000.00
NEPHROPLUS.NS balance_sheet (annual, 2026-03-31) — Stockholders Equity: 11164930000.00
NEPHROPLUS.NS balance_sheet (quarterly, 2026-03-31) — Stockholders Equity: 11164930000.00
NEPHROPLUS.NS balance_sheet (annual, 2026-03-31) — Tangible Book Value: 9959340000.00
NEPHROPLUS.NS balance_sheet (quarterly, 2026-03-31) — Tangible Book Value: 9959340000.00
NEPHROPLUS.NS income_statement (annual, 2026-03-31) — Tax Effect Of Unusual Items: 13723682.42
NEPHROPLUS.NS income_statement (quarterly, 2026-03-31) — Tax Effect Of Unusual Items: 0.00
NEPHROPLUS.NS income_statement (annual, 2026-03-31) — Tax Provision: 206340000.00
NEPHROPLUS.NS income_statement (quarterly, 2026-03-31) — Tax Provision: 28490000.00
NEPHROPLUS.NS income_statement (annual, 2026-03-31) — Tax Rate For Calcs: 0.21
NEPHROPLUS.NS income_statement (quarterly, 2026-03-31) — Tax Rate For Calcs: 0.09
NEPHROPLUS.NS cash_flow (annual, 2026-03-31) — Taxes Refund Paid: -274770000.00
NEPHROPLUS.NS balance_sheet (annual, 2026-03-31) — Total Assets: 14708660000.00
NEPHROPLUS.NS balance_sheet (quarterly, 2026-03-31) — Total Assets: 14708660000.00
NEPHROPLUS.NS balance_sheet (annual, 2026-03-31) — Total Capitalization: 11165400000.00
NEPHROPLUS.NS balance_sheet (quarterly, 2026-03-31) — Total Capitalization: 11165400000.00
NEPHROPLUS.NS balance_sheet (annual, 2026-03-31) — Total Debt: 797070000.00
NEPHROPLUS.NS balance_sheet (quarterly, 2026-03-31) — Total Debt: 797070000.00
NEPHROPLUS.NS balance_sheet (annual, 2026-03-31) — Total Equity Gross Minority Interest: 11164930000.00
NEPHROPLUS.NS balance_sheet (quarterly, 2026-03-31) — Total Equity Gross Minority Interest: 11164930000.00
NEPHROPLUS.NS income_statement (annual, 2026-03-31) — Total Expenses: 8555200000.00
NEPHROPLUS.NS income_statement (quarterly, 2026-03-31) — Total Expenses: 2376920000.00
NEPHROPLUS.NS balance_sheet (annual, 2026-03-31) — Total Liabilities Net Minority Interest: 3543730000.00
NEPHROPLUS.NS balance_sheet (quarterly, 2026-03-31) — Total Liabilities Net Minority Interest: 3543730000.00
NEPHROPLUS.NS balance_sheet (annual, 2026-03-31) — Total Non Current Assets: 6316980000.00
NEPHROPLUS.NS balance_sheet (quarterly, 2026-03-31) — Total Non Current Assets: 6316980000.00
NEPHROPLUS.NS balance_sheet (annual, 2026-03-31) — Total Non Current Liabilities Net Minority Interest: 549620000.00
NEPHROPLUS.NS balance_sheet (quarterly, 2026-03-31) — Total Non Current Liabilities Net Minority Interest: 549620000.00
NEPHROPLUS.NS income_statement (annual, 2026-03-31) — Total Other Finance Cost: 22760000.00
NEPHROPLUS.NS balance_sheet (annual, 2026-03-31) — Total Tax Payable: 166520000.00
NEPHROPLUS.NS balance_sheet (quarterly, 2026-03-31) — Total Tax Payable: 166520000.00
NEPHROPLUS.NS income_statement (annual, 2026-03-31) — Total Unusual Items: 64830000.00
NEPHROPLUS.NS income_statement (annual, 2026-03-31) — Total Unusual Items Excluding Goodwill: 64830000.00
NEPHROPLUS.NS balance_sheet (annual, 2026-03-31) — Tradeand Other Payables Non Current: 1070000.00
NEPHROPLUS.NS balance_sheet (quarterly, 2026-03-31) — Tradeand Other Payables Non Current: 1070000.00
NEPHROPLUS.NS balance_sheet (annual, 2026-03-31) — Working Capital: 5397570000.00
NEPHROPLUS.NS balance_sheet (quarterly, 2026-03-31) — Working Capital: 5397570000.00
NEPHROPLUS.NS income_statement (annual, 2026-03-31) — Write Off: 1940000.00
NERV cash_flow (annual, 2021-12-31) — Amortization Of Securities: 0.00
NERV cash_flow (annual, 2021-12-31) — Asset Impairment Charge: 15200000.00
NERV balance_sheet (annual, 2021-12-31) — Buildings And Improvements: 0.00
NERV balance_sheet (annual, 2021-12-31) — Capital Lease Obligations: 0.00
NERV cash_flow (annual, 2021-12-31) — Cash Flow From Continuing Investing Activities: 0.00
NERV cash_flow (annual, 2021-12-31) — Change In Other Current Assets: -36272.00
NERV cash_flow (annual, 2021-12-31) — Change In Other Current Liabilities: -111229.00
NERV cash_flow (annual, 2021-12-31) — Common Stock Issuance: 0.00
NERV balance_sheet (annual, 2021-12-31) — Current Capital Lease Obligation: 0.00
NERV cash_flow (annual, 2021-12-31) — Deferred Income Tax: -1803356.00
NERV cash_flow (annual, 2021-12-31) — Deferred Tax: -1803356.00
NERV balance_sheet (annual, 2021-12-31) — Gross PPE: 0.00
NERV income_statement (annual, 2021-12-31) — Interest Income: 16516.00
NERV income_statement (annual, 2021-12-31) — Interest Income Non Operating: 16516.00
NERV cash_flow (annual, 2021-12-31) — Interest Paid Supplemental Data: 0.00
NERV cash_flow (annual, 2021-12-31) — Net Common Stock Issuance: 0.00
NERV cash_flow (annual, 2021-12-31) — Net Investment Purchase And Sale: 0.00
NERV cash_flow (annual, 2021-12-31) — Net Other Financing Charges: 60000000.00
NERV cash_flow (annual, 2021-12-31) — Net PPE Purchase And Sale: 0.00
NERV balance_sheet (annual, 2021-12-31) — Non Current Deferred Liabilities: 0.00
NERV balance_sheet (annual, 2021-12-31) — Non Current Deferred Taxes Liabilities: 0.00
NERV balance_sheet (annual, 2021-12-31) — Other Intangible Assets: 51080.00
NERV cash_flow (annual, 2021-12-31) — Other Non Cash Items: 6327321.00
NERV balance_sheet (annual, 2021-12-31) — Preferred Stock: 0.00
NERV balance_sheet (annual, 2021-12-31) — Prepaid Assets: 1346359.00
NERV cash_flow (annual, 2021-12-31) — Proceeds From Stock Option Exercised: 0.00
NERV balance_sheet (annual, 2021-12-31) — Properties: 0.00
NERV cash_flow (annual, 2021-12-31) — Purchase Of Investment: 0.00
NERV cash_flow (annual, 2021-12-31) — Purchase Of PPE: 0.00
NERV cash_flow (annual, 2021-12-31) — Sale Of Investment: 0.00
NERV income_statement (annual, 2021-12-31) — Tax Provision: -1803356.00
NERV balance_sheet (annual, 2021-12-31) — Total Debt: 0.00
NERV income_statement (annual, 2022-12-31) — +Operating Expense: 25231326.00
NERV income_statement (annual, 2022-12-31) — +Total Revenue: 0.00
NERV balance_sheet (annual, 2022-12-31) — Accounts Payable: 969667.00
NERV balance_sheet (annual, 2022-12-31) — Additional Paid In Capital: 346785322.00
NERV cash_flow (annual, 2022-12-31) — Amortization Cash Flow: 8513.00
NERV cash_flow (annual, 2022-12-31) — Amortization Of Intangibles: 8513.00
NERV cash_flow (annual, 2022-12-31) — Asset Impairment Charge: 0.00
NERV income_statement (annual, 2022-12-31) — Basic Average Shares: 5340194.00
NERV income_statement (annual, 2022-12-31) — Basic EPS: -6.01
NERV cash_flow (annual, 2022-12-31) — Beginning Cash Position: 60855080.00
NERV cash_flow (annual, 2022-12-31) — Capital Expenditure: -16326.00
NERV balance_sheet (annual, 2022-12-31) — Capital Stock: 534.00
NERV balance_sheet (annual, 2022-12-31) — Cash And Cash Equivalents: 36093606.00
NERV balance_sheet (annual, 2022-12-31) — Cash Cash Equivalents And Short Term Investments: 36093606.00
NERV cash_flow (annual, 2022-12-31) — Cash Flow From Continuing Financing Activities: -5.00
NERV cash_flow (annual, 2022-12-31) — Cash Flow From Continuing Investing Activities: -16326.00
NERV cash_flow (annual, 2022-12-31) — Cash Flow From Continuing Operating Activities: -24645143.00
NERV cash_flow (annual, 2022-12-31) — Change In Account Payable: -883548.00
NERV cash_flow (annual, 2022-12-31) — Change In Accrued Expense: -557830.00
NERV cash_flow (annual, 2022-12-31) — Change In Other Current Assets: -3117218.00
NERV cash_flow (annual, 2022-12-31) — Change In Other Current Liabilities: 0.00
NERV cash_flow (annual, 2022-12-31) — Change In Other Working Capital: -3117218.00
NERV cash_flow (annual, 2022-12-31) — Change In Payable: -883548.00
NERV cash_flow (annual, 2022-12-31) — Change In Payables And Accrued Expense: -1441378.00
NERV cash_flow (annual, 2022-12-31) — Change In Prepaid Assets: 498242.00
NERV cash_flow (annual, 2022-12-31) — Change In Working Capital: -4060354.00
NERV cash_flow (annual, 2022-12-31) — Changes In Cash: -24661474.00
NERV balance_sheet (annual, 2022-12-31) — Common Stock: 534.00
NERV balance_sheet (annual, 2022-12-31) — Common Stock Equity: -20024219.00
NERV cash_flow (annual, 2022-12-31) — Common Stock Issuance: 0.00
NERV balance_sheet (annual, 2022-12-31) — Current Accrued Expenses: 393077.00
NERV balance_sheet (annual, 2022-12-31) — Current Assets: 40158941.00
NERV balance_sheet (annual, 2022-12-31) — Current Liabilities: 1377576.00
NERV cash_flow (annual, 2022-12-31) — Depreciation: 0.00
NERV cash_flow (annual, 2022-12-31) — Depreciation Amortization Depletion: 8513.00
NERV cash_flow (annual, 2022-12-31) — Depreciation And Amortization: 8513.00
NERV income_statement (annual, 2022-12-31) — Diluted Average Shares: 5340194.00
NERV income_statement (annual, 2022-12-31) — Diluted EPS: -6.01
NERV income_statement (annual, 2022-12-31) — Diluted NI Availto Com Stockholders: -32108676.00
NERV income_statement (annual, 2022-12-31) — EBIT: -24702121.00
NERV income_statement (annual, 2022-12-31) — EBITDA: -24693608.00
NERV cash_flow (annual, 2022-12-31) — End Cash Position: 36193606.00
NERV cash_flow (annual, 2022-12-31) — Financing Cash Flow: -5.00
NERV cash_flow (annual, 2022-12-31) — Free Cash Flow: -24661469.00
NERV income_statement (annual, 2022-12-31) — Gain On Sale Of Security: 529205.00
NERV income_statement (annual, 2022-12-31) — General And Administrative Expense: 10582239.00
NERV balance_sheet (annual, 2022-12-31) — Goodwill: 14869399.00
NERV balance_sheet (annual, 2022-12-31) — Goodwill And Other Intangible Assets: 14911966.00
NERV balance_sheet (annual, 2022-12-31) — Gross PPE: 16326.00
NERV income_statement (annual, 2022-12-31) — Interest Expense: 7406555.00
NERV income_statement (annual, 2022-12-31) — Interest Expense Non Operating: 7406555.00
NERV income_statement (annual, 2022-12-31) — Interest Income: 556946.00
NERV income_statement (annual, 2022-12-31) — Interest Income Non Operating: 556946.00
NERV balance_sheet (annual, 2022-12-31) — Invested Capital: -20024219.00
NERV cash_flow (annual, 2022-12-31) — Investing Cash Flow: -16326.00
NERV cash_flow (annual, 2022-12-31) — Issuance Of Capital Stock: 0.00
NERV cash_flow (annual, 2022-12-31) — Net Common Stock Issuance: 0.00
NERV income_statement (annual, 2022-12-31) — Net Income: -32108676.00
NERV income_statement (annual, 2022-12-31) — Net Income Common Stockholders: -32108676.00
NERV income_statement (annual, 2022-12-31) — Net Income Continuous Operations: -32108676.00
NERV income_statement (annual, 2022-12-31) — Net Income From Continuing And Discontinued Operation: -32108676.00
NERV income_statement (annual, 2022-12-31) — Net Income From Continuing Operation Net Minority Interest: -32108676.00
NERV cash_flow (annual, 2022-12-31) — Net Income From Continuing Operations: -32108676.00
NERV income_statement (annual, 2022-12-31) — Net Income Including Noncontrolling Interests: -32108676.00
NERV income_statement (annual, 2022-12-31) — Net Interest Income: -7406555.00
NERV income_statement (annual, 2022-12-31) — Net Non Operating Interest Income Expense: -7406555.00
NERV cash_flow (annual, 2022-12-31) — Net Other Financing Charges: -5.00
NERV balance_sheet (annual, 2022-12-31) — Net PPE: 16326.00
NERV cash_flow (annual, 2022-12-31) — Net PPE Purchase And Sale: -16326.00
NERV balance_sheet (annual, 2022-12-31) — Net Tangible Assets: -34936185.00
NERV income_statement (annual, 2022-12-31) — Normalized EBITDA: -25222813.00
NERV income_statement (annual, 2022-12-31) — Normalized Income: -32637881.00
NERV cash_flow (annual, 2022-12-31) — Operating Cash Flow: -24645143.00
NERV income_statement (annual, 2022-12-31) — Operating Income: -25231326.00
NERV income_statement (annual, 2022-12-31) — Operating Revenue: 0.00
NERV balance_sheet (annual, 2022-12-31) — Ordinary Shares Number: 5340193.00
NERV balance_sheet (annual, 2022-12-31) — Other Current Assets: 3965335.00
NERV income_statement (annual, 2022-12-31) — Other Gand A: 10582239.00
NERV income_statement (annual, 2022-12-31) — Other Income Expense: 529205.00
NERV balance_sheet (annual, 2022-12-31) — Other Intangible Assets: 42567.00
NERV cash_flow (annual, 2022-12-31) — Other Non Cash Items: 7406555.00
NERV balance_sheet (annual, 2022-12-31) — Other Non Current Liabilities: 73733876.00
NERV balance_sheet (annual, 2022-12-31) — Other Properties: 16326.00
NERV balance_sheet (annual, 2022-12-31) — Payables: 969667.00
NERV balance_sheet (annual, 2022-12-31) — Payables And Accrued Expenses: 1362744.00
NERV balance_sheet (annual, 2022-12-31) — Pensionand Other Post Retirement Benefit Plans Current: 14832.00
NERV balance_sheet (annual, 2022-12-31) — Preferred Stock: 0.00
NERV income_statement (annual, 2022-12-31) — Pretax Income: -32108676.00
NERV cash_flow (annual, 2022-12-31) — Purchase Of PPE: -16326.00
NERV income_statement (annual, 2022-12-31) — Reconciled Depreciation: 8513.00
NERV income_statement (annual, 2022-12-31) — Research And Development: 14649087.00
NERV balance_sheet (annual, 2022-12-31) — Restricted Cash: 100000.00
NERV balance_sheet (annual, 2022-12-31) — Retained Earnings: -366810075.00
NERV income_statement (annual, 2022-12-31) — Selling General And Administration: 10582239.00
NERV balance_sheet (annual, 2022-12-31) — Share Issued: 5340193.00
NERV cash_flow (annual, 2022-12-31) — Stock Based Compensation: 4108819.00
NERV balance_sheet (annual, 2022-12-31) — Stockholders Equity: -20024219.00
NERV balance_sheet (annual, 2022-12-31) — Tangible Book Value: -34936185.00
NERV income_statement (annual, 2022-12-31) — Tax Effect Of Unusual Items: 0.00
NERV income_statement (annual, 2022-12-31) — Tax Provision: 0.00
NERV income_statement (annual, 2022-12-31) — Tax Rate For Calcs: 0.00
NERV balance_sheet (annual, 2022-12-31) — Total Assets: 55087233.00
NERV balance_sheet (annual, 2022-12-31) — Total Capitalization: -20024219.00
NERV balance_sheet (annual, 2022-12-31) — Total Equity Gross Minority Interest: -20024219.00
NERV income_statement (annual, 2022-12-31) — Total Expenses: 25231326.00
NERV balance_sheet (annual, 2022-12-31) — Total Liabilities Net Minority Interest: 75111452.00
NERV balance_sheet (annual, 2022-12-31) — Total Non Current Assets: 14928292.00
NERV balance_sheet (annual, 2022-12-31) — Total Non Current Liabilities Net Minority Interest: 73733876.00
NERV income_statement (annual, 2022-12-31) — Total Operating Income As Reported: -25231326.00
NERV income_statement (annual, 2022-12-31) — Total Unusual Items: 529205.00
NERV income_statement (annual, 2022-12-31) — Total Unusual Items Excluding Goodwill: 529205.00
NERV balance_sheet (annual, 2022-12-31) — Working Capital: 38781365.00
NERV income_statement (annual, 2023-12-31) — +Operating Expense: 23119576.00
NERV income_statement (annual, 2023-12-31) — +Total Revenue: 0.00
NERV balance_sheet (annual, 2023-12-31) — Accounts Payable: 1805320.00
NERV balance_sheet (annual, 2023-12-31) — Additional Paid In Capital: 368357239.00
NERV cash_flow (annual, 2023-12-31) — Amortization Cash Flow: 25540.00
NERV cash_flow (annual, 2023-12-31) — Amortization Of Intangibles: 25540.00
NERV income_statement (annual, 2023-12-31) — Basic Average Shares: 6506372.00
NERV income_statement (annual, 2023-12-31) — Basic EPS: -4.61
NERV cash_flow (annual, 2023-12-31) — Beginning Cash Position: 36193606.00
NERV balance_sheet (annual, 2023-12-31) — Capital Stock: 699.00
NERV balance_sheet (annual, 2023-12-31) — Cash And Cash Equivalents: 40912575.00
NERV balance_sheet (annual, 2023-12-31) — Cash Cash Equivalents And Short Term Investments: 40912575.00
NERV cash_flow (annual, 2023-12-31) — Cash Flow From Continuing Financing Activities: 19603701.00
NERV cash_flow (annual, 2023-12-31) — Cash Flow From Continuing Investing Activities: 0.00
NERV cash_flow (annual, 2023-12-31) — Cash Flow From Continuing Operating Activities: -14784732.00
NERV cash_flow (annual, 2023-12-31) — Change In Account Payable: 835653.00
NERV cash_flow (annual, 2023-12-31) — Change In Accrued Expense: 1127188.00
NERV cash_flow (annual, 2023-12-31) — Change In Other Current Assets: 3117218.00
NERV cash_flow (annual, 2023-12-31) — Change In Payable: 835653.00
NERV cash_flow (annual, 2023-12-31) — Change In Payables And Accrued Expense: 1962841.00
NERV cash_flow (annual, 2023-12-31) — Change In Prepaid Assets: -141748.00
NERV cash_flow (annual, 2023-12-31) — Change In Working Capital: 4938311.00
NERV cash_flow (annual, 2023-12-31) — Changes In Cash: 4818969.00
NERV balance_sheet (annual, 2023-12-31) — Common Stock: 699.00
NERV balance_sheet (annual, 2023-12-31) — Common Stock Equity: -28457490.00
NERV cash_flow (annual, 2023-12-31) — Common Stock Issuance: 19999994.00
NERV balance_sheet (annual, 2023-12-31) — Current Accrued Expenses: 944328.00
NERV balance_sheet (annual, 2023-12-31) — Current Assets: 42002440.00
NERV balance_sheet (annual, 2023-12-31) — Current Liabilities: 3340417.00
NERV cash_flow (annual, 2023-12-31) — Depreciation: 5442.00
NERV cash_flow (annual, 2023-12-31) — Depreciation Amortization Depletion: 30982.00
NERV cash_flow (annual, 2023-12-31) — Depreciation And Amortization: 30982.00
NERV income_statement (annual, 2023-12-31) — Diluted Average Shares: 6506372.00
NERV income_statement (annual, 2023-12-31) — Diluted EPS: -4.61
NERV income_statement (annual, 2023-12-31) — Diluted NI Availto Com Stockholders: -30005353.00
NERV income_statement (annual, 2023-12-31) — EBIT: -21722406.00
NERV income_statement (annual, 2023-12-31) — EBITDA: -21691424.00
NERV cash_flow (annual, 2023-12-31) — End Cash Position: 41012575.00
NERV cash_flow (annual, 2023-12-31) — Financing Cash Flow: 19603701.00
NERV cash_flow (annual, 2023-12-31) — Free Cash Flow: -14784732.00
NERV income_statement (annual, 2023-12-31) — Gain On Sale Of Security: 1397170.00
NERV income_statement (annual, 2023-12-31) — General And Administrative Expense: 10414323.00
NERV balance_sheet (annual, 2023-12-31) — Goodwill: 14869399.00
NERV balance_sheet (annual, 2023-12-31) — Goodwill And Other Intangible Assets: 14886426.00
NERV income_statement (annual, 2023-12-31) — Interest Expense: 8282947.00
NERV income_statement (annual, 2023-12-31) — Interest Expense Non Operating: 8282947.00
NERV income_statement (annual, 2023-12-31) — Interest Income: 1437405.00
NERV income_statement (annual, 2023-12-31) — Interest Income Non Operating: 1437405.00
NERV balance_sheet (annual, 2023-12-31) — Invested Capital: -28457490.00
NERV cash_flow (annual, 2023-12-31) — Investing Cash Flow: 0.00
NERV cash_flow (annual, 2023-12-31) — Issuance Of Capital Stock: 19999994.00
NERV cash_flow (annual, 2023-12-31) — Net Common Stock Issuance: 19999994.00
NERV income_statement (annual, 2023-12-31) — Net Income: -30005353.00
NERV income_statement (annual, 2023-12-31) — Net Income Common Stockholders: -30005353.00
NERV income_statement (annual, 2023-12-31) — Net Income Continuous Operations: -30005353.00
NERV income_statement (annual, 2023-12-31) — Net Income From Continuing And Discontinued Operation: -30005353.00
NERV income_statement (annual, 2023-12-31) — Net Income From Continuing Operation Net Minority Interest: -30005353.00
NERV cash_flow (annual, 2023-12-31) — Net Income From Continuing Operations: -30005353.00
NERV income_statement (annual, 2023-12-31) — Net Income Including Noncontrolling Interests: -30005353.00
NERV income_statement (annual, 2023-12-31) — Net Interest Income: -8282947.00
NERV income_statement (annual, 2023-12-31) — Net Non Operating Interest Income Expense: -8282947.00
NERV cash_flow (annual, 2023-12-31) — Net Other Financing Charges: -396293.00
NERV balance_sheet (annual, 2023-12-31) — Net PPE: 10884.00
NERV cash_flow (annual, 2023-12-31) — Net PPE Purchase And Sale: 0.00
NERV balance_sheet (annual, 2023-12-31) — Net Tangible Assets: -43343916.00
NERV income_statement (annual, 2023-12-31) — Normalized EBITDA: -23088594.00
NERV income_statement (annual, 2023-12-31) — Normalized Income: -31402523.00
NERV cash_flow (annual, 2023-12-31) — Operating Cash Flow: -14784732.00
NERV income_statement (annual, 2023-12-31) — Operating Income: -23119576.00
NERV income_statement (annual, 2023-12-31) — Operating Revenue: 0.00
NERV balance_sheet (annual, 2023-12-31) — Ordinary Shares Number: 6993406.00
NERV balance_sheet (annual, 2023-12-31) — Other Current Assets: 989865.00
NERV income_statement (annual, 2023-12-31) — Other Gand A: 10414323.00
NERV income_statement (annual, 2023-12-31) — Other Income Expense: 1397170.00
NERV balance_sheet (annual, 2023-12-31) — Other Intangible Assets: 17027.00
NERV cash_flow (annual, 2023-12-31) — Other Non Cash Items: 8282947.00
NERV balance_sheet (annual, 2023-12-31) — Other Non Current Liabilities: 82016823.00
NERV balance_sheet (annual, 2023-12-31) — Payables: 1805320.00
NERV balance_sheet (annual, 2023-12-31) — Payables And Accrued Expenses: 2749648.00
NERV balance_sheet (annual, 2023-12-31) — Pensionand Other Post Retirement Benefit Plans Current: 590769.00
NERV balance_sheet (annual, 2023-12-31) — Preferred Stock: 0.00
NERV income_statement (annual, 2023-12-31) — Pretax Income: -30005353.00
NERV cash_flow (annual, 2023-12-31) — Purchase Of PPE: 0.00
NERV income_statement (annual, 2023-12-31) — Reconciled Depreciation: 30982.00
NERV income_statement (annual, 2023-12-31) — Research And Development: 12705253.00
NERV balance_sheet (annual, 2023-12-31) — Restricted Cash: 100000.00
NERV balance_sheet (annual, 2023-12-31) — Retained Earnings: -396815428.00
NERV income_statement (annual, 2023-12-31) — Selling General And Administration: 10414323.00
NERV balance_sheet (annual, 2023-12-31) — Share Issued: 6993406.00
NERV cash_flow (annual, 2023-12-31) — Stock Based Compensation: 1968381.00
NERV balance_sheet (annual, 2023-12-31) — Stockholders Equity: -28457490.00
NERV balance_sheet (annual, 2023-12-31) — Tangible Book Value: -43343916.00
NERV income_statement (annual, 2023-12-31) — Tax Effect Of Unusual Items: 0.00
NERV income_statement (annual, 2023-12-31) — Tax Rate For Calcs: 0.00
NERV balance_sheet (annual, 2023-12-31) — Total Assets: 56899750.00
NERV balance_sheet (annual, 2023-12-31) — Total Capitalization: -28457490.00
NERV balance_sheet (annual, 2023-12-31) — Total Equity Gross Minority Interest: -28457490.00
NERV income_statement (annual, 2023-12-31) — Total Expenses: 23119576.00
NERV balance_sheet (annual, 2023-12-31) — Total Liabilities Net Minority Interest: 85357240.00
NERV balance_sheet (annual, 2023-12-31) — Total Non Current Assets: 14897310.00
NERV balance_sheet (annual, 2023-12-31) — Total Non Current Liabilities Net Minority Interest: 82016823.00
NERV income_statement (annual, 2023-12-31) — Total Operating Income As Reported: -23119576.00
NERV income_statement (annual, 2023-12-31) — Total Unusual Items: 1397170.00
NERV income_statement (annual, 2023-12-31) — Total Unusual Items Excluding Goodwill: 1397170.00
NERV balance_sheet (annual, 2023-12-31) — Working Capital: 38662023.00
NERV cash_flow (quarterly, 2024-09-30) — Cash Flow From Continuing Financing Activities: 0.00
NERV cash_flow (quarterly, 2024-09-30) — Common Stock Issuance: 0.00
NERV cash_flow (quarterly, 2024-09-30) — Issuance Of Capital Stock: 0.00
NERV cash_flow (quarterly, 2024-09-30) — Net Common Stock Issuance: 0.00
NERV cash_flow (quarterly, 2024-09-30) — Other Non Cash Items: -26579046.00
NERV income_statement (quarterly, 2024-09-30) — Other Non Operating Income Expenses: 26579046.00
NERV balance_sheet (quarterly, 2024-09-30) — Preferred Stock: 0.00
NERV income_statement (annual, 2024-12-31) — +Operating Expense: 21848386.00
NERV income_statement (annual, 2024-12-31) — +Total Revenue: 0.00
NERV balance_sheet (annual, 2024-12-31) — Accounts Payable: 1607844.00
NERV balance_sheet (annual, 2024-12-31) — Additional Paid In Capital: 369682764.00
NERV cash_flow (annual, 2024-12-31) — Amortization Cash Flow: 17027.00
NERV cash_flow (quarterly, 2024-12-31) — Amortization Cash Flow: 0.00
NERV cash_flow (annual, 2024-12-31) — Amortization Of Intangibles: 17027.00
NERV cash_flow (quarterly, 2024-12-31) — Amortization Of Intangibles: 0.00
NERV income_statement (annual, 2024-12-31) — Basic Average Shares: 7568981.00
NERV income_statement (annual, 2024-12-31) — Basic EPS: 0.19
NERV cash_flow (annual, 2024-12-31) — Beginning Cash Position: 41012575.00
NERV balance_sheet (annual, 2024-12-31) — Capital Stock: 699.00
NERV balance_sheet (annual, 2024-12-31) — Cash And Cash Equivalents: 21362008.00
NERV balance_sheet (annual, 2024-12-31) — Cash Cash Equivalents And Short Term Investments: 21362008.00
NERV cash_flow (annual, 2024-12-31) — Cash Flow From Continuing Financing Activities: 0.00
NERV cash_flow (quarterly, 2024-12-31) — Cash Flow From Continuing Financing Activities: 0.00
NERV cash_flow (annual, 2024-12-31) — Cash Flow From Continuing Operating Activities: -19550567.00
NERV cash_flow (annual, 2024-12-31) — Change In Account Payable: -197476.00
NERV cash_flow (annual, 2024-12-31) — Change In Accrued Expense: -306097.00
NERV cash_flow (annual, 2024-12-31) — Change In Other Current Assets: 0.00
NERV cash_flow (annual, 2024-12-31) — Change In Payable: -197476.00
NERV cash_flow (annual, 2024-12-31) — Change In Payables And Accrued Expense: -503573.00
NERV cash_flow (annual, 2024-12-31) — Change In Prepaid Assets: 182970.00
NERV cash_flow (annual, 2024-12-31) — Change In Working Capital: -320603.00
NERV cash_flow (annual, 2024-12-31) — Changes In Cash: -19550567.00
NERV balance_sheet (annual, 2024-12-31) — Common Stock: 699.00
NERV balance_sheet (annual, 2024-12-31) — Common Stock Equity: -25693100.00
NERV cash_flow (annual, 2024-12-31) — Common Stock Issuance: 0.00
NERV cash_flow (quarterly, 2024-12-31) — Common Stock Issuance: 0.00
NERV balance_sheet (annual, 2024-12-31) — Current Accrued Expenses: 865819.00
NERV balance_sheet (annual, 2024-12-31) — Current Assets: 22268903.00
NERV balance_sheet (annual, 2024-12-31) — Current Liabilities: 2836844.00
NERV cash_flow (annual, 2024-12-31) — Depreciation: 5442.00
NERV cash_flow (annual, 2024-12-31) — Depreciation Amortization Depletion: 22469.00
NERV cash_flow (annual, 2024-12-31) — Depreciation And Amortization: 22469.00
NERV balance_sheet (annual, 2024-12-31) — Derivative Product Liabilities: 0.00
NERV balance_sheet (quarterly, 2024-12-31) — Derivative Product Liabilities: 0.00
NERV income_statement (annual, 2024-12-31) — Diluted Average Shares: 7573763.00
NERV income_statement (annual, 2024-12-31) — Diluted EPS: 0.19
NERV income_statement (annual, 2024-12-31) — Diluted NI Availto Com Stockholders: 1438865.00
NERV income_statement (annual, 2024-12-31) — EBIT: 6001088.00
NERV income_statement (annual, 2024-12-31) — EBITDA: 6023557.00
NERV cash_flow (annual, 2024-12-31) — End Cash Position: 21462008.00
NERV cash_flow (annual, 2024-12-31) — Financing Cash Flow: 0.00
NERV cash_flow (annual, 2024-12-31) — Free Cash Flow: -19550567.00
NERV income_statement (annual, 2024-12-31) — Gain On Sale Of Security: 1270428.00
NERV income_statement (annual, 2024-12-31) — General And Administrative Expense: 9949791.00
NERV balance_sheet (annual, 2024-12-31) — Goodwill: 14869399.00
NERV balance_sheet (annual, 2024-12-31) — Goodwill And Other Intangible Assets: 14869399.00
NERV income_statement (annual, 2024-12-31) — Interest Expense: 4562223.00
NERV income_statement (quarterly, 2024-12-31) — Interest Expense: 0.00
NERV income_statement (annual, 2024-12-31) — Interest Expense Non Operating: 4562223.00
NERV income_statement (quarterly, 2024-12-31) — Interest Expense Non Operating: 0.00
NERV balance_sheet (annual, 2024-12-31) — Invested Capital: -25693100.00
NERV cash_flow (annual, 2024-12-31) — Investing Cash Flow: 0.00
NERV cash_flow (annual, 2024-12-31) — Issuance Of Capital Stock: 0.00
NERV cash_flow (quarterly, 2024-12-31) — Issuance Of Capital Stock: 0.00
NERV cash_flow (annual, 2024-12-31) — Net Common Stock Issuance: 0.00
NERV cash_flow (quarterly, 2024-12-31) — Net Common Stock Issuance: 0.00
NERV income_statement (annual, 2024-12-31) — Net Income: 1438865.00
NERV income_statement (annual, 2024-12-31) — Net Income Common Stockholders: 1438865.00
NERV income_statement (annual, 2024-12-31) — Net Income Continuous Operations: 1438865.00
NERV income_statement (annual, 2024-12-31) — Net Income From Continuing And Discontinued Operation: 1438865.00
NERV income_statement (annual, 2024-12-31) — Net Income From Continuing Operation Net Minority Interest: 1438865.00
NERV cash_flow (annual, 2024-12-31) — Net Income From Continuing Operations: 1438865.00
NERV income_statement (annual, 2024-12-31) — Net Income Including Noncontrolling Interests: 1438865.00
NERV income_statement (annual, 2024-12-31) — Net Interest Income: -4562223.00
NERV income_statement (quarterly, 2024-12-31) — Net Interest Income: 0.00
NERV income_statement (annual, 2024-12-31) — Net Non Operating Interest Income Expense: -4562223.00
NERV income_statement (quarterly, 2024-12-31) — Net Non Operating Interest Income Expense: 0.00
NERV balance_sheet (annual, 2024-12-31) — Net PPE: 5442.00
NERV balance_sheet (quarterly, 2024-12-31) — Net PPE: 5442.00
NERV cash_flow (annual, 2024-12-31) — Net Preferred Stock Issuance: 0.00
NERV balance_sheet (annual, 2024-12-31) — Net Tangible Assets: -40562499.00
NERV income_statement (annual, 2024-12-31) — Normalized EBITDA: 4753129.00
NERV income_statement (annual, 2024-12-31) — Normalized Income: 168437.00
NERV cash_flow (annual, 2024-12-31) — Operating Cash Flow: -19550567.00
NERV income_statement (annual, 2024-12-31) — Operating Income: -21848386.00
NERV income_statement (annual, 2024-12-31) — Operating Revenue: 0.00
NERV balance_sheet (annual, 2024-12-31) — Ordinary Shares Number: 6993406.00
NERV balance_sheet (annual, 2024-12-31) — Other Current Assets: 806895.00
NERV income_statement (annual, 2024-12-31) — Other Gand A: 9949791.00
NERV income_statement (annual, 2024-12-31) — Other Income Expense: 27849474.00
NERV cash_flow (annual, 2024-12-31) — Other Non Cash Items: -22016823.00
NERV cash_flow (quarterly, 2024-12-31) — Other Non Cash Items: 0.00
NERV balance_sheet (annual, 2024-12-31) — Other Non Current Liabilities: 60000000.00
NERV income_statement (annual, 2024-12-31) — Other Non Operating Income Expenses: 26579046.00
NERV income_statement (quarterly, 2024-12-31) — Other Non Operating Income Expenses: 0.00
NERV balance_sheet (annual, 2024-12-31) — Payables: 1607844.00
NERV balance_sheet (annual, 2024-12-31) — Payables And Accrued Expenses: 2473663.00
NERV balance_sheet (annual, 2024-12-31) — Pensionand Other Post Retirement Benefit Plans Current: 363181.00
NERV balance_sheet (annual, 2024-12-31) — Preferred Securities Outside Stock Equity: 0.00
NERV balance_sheet (quarterly, 2024-12-31) — Preferred Securities Outside Stock Equity: 0.00
NERV balance_sheet (annual, 2024-12-31) — Preferred Stock: 0.00
NERV balance_sheet (quarterly, 2024-12-31) — Preferred Stock: 0.00
NERV cash_flow (annual, 2024-12-31) — Preferred Stock Issuance: 0.00
NERV income_statement (annual, 2024-12-31) — Pretax Income: 1438865.00
NERV income_statement (annual, 2024-12-31) — Reconciled Depreciation: 22469.00
NERV income_statement (annual, 2024-12-31) — Research And Development: 11898595.00
NERV balance_sheet (annual, 2024-12-31) — Restricted Cash: 100000.00
NERV balance_sheet (annual, 2024-12-31) — Retained Earnings: -395376563.00
NERV income_statement (annual, 2024-12-31) — Selling General And Administration: 9949791.00
NERV balance_sheet (annual, 2024-12-31) — Share Issued: 6993406.00
NERV cash_flow (annual, 2024-12-31) — Stock Based Compensation: 1325525.00
NERV balance_sheet (annual, 2024-12-31) — Stockholders Equity: -25693100.00
NERV balance_sheet (annual, 2024-12-31) — Tangible Book Value: -40562499.00
NERV income_statement (annual, 2024-12-31) — Tax Effect Of Unusual Items: 0.00
NERV income_statement (annual, 2024-12-31) — Tax Rate For Calcs: 0.00
NERV balance_sheet (annual, 2024-12-31) — Total Assets: 37143744.00
NERV balance_sheet (annual, 2024-12-31) — Total Capitalization: -25693100.00
NERV balance_sheet (annual, 2024-12-31) — Total Equity Gross Minority Interest: -25693100.00
NERV income_statement (annual, 2024-12-31) — Total Expenses: 21848386.00
NERV balance_sheet (annual, 2024-12-31) — Total Liabilities Net Minority Interest: 62836844.00
NERV balance_sheet (annual, 2024-12-31) — Total Non Current Assets: 14874841.00
NERV balance_sheet (annual, 2024-12-31) — Total Non Current Liabilities Net Minority Interest: 60000000.00
NERV income_statement (annual, 2024-12-31) — Total Operating Income As Reported: -21848386.00
NERV income_statement (annual, 2024-12-31) — Total Unusual Items: 1270428.00
NERV income_statement (annual, 2024-12-31) — Total Unusual Items Excluding Goodwill: 1270428.00
NERV balance_sheet (annual, 2024-12-31) — Working Capital: 19432059.00
NERV income_statement (quarterly, 2025-03-31) — +Operating Expense: 3902884.00
NERV income_statement (quarterly, 2025-03-31) — +Total Revenue: 0.00
NERV balance_sheet (quarterly, 2025-03-31) — Accounts Payable: 639946.00
NERV balance_sheet (quarterly, 2025-03-31) — Additional Paid In Capital: 369979993.00
NERV cash_flow (quarterly, 2025-03-31) — Amortization Cash Flow: 0.00
NERV cash_flow (quarterly, 2025-03-31) — Amortization Of Intangibles: 0.00
NERV cash_flow (quarterly, 2025-03-31) — Amortization Of Securities: 0.00
NERV income_statement (quarterly, 2025-03-31) — Basic Average Shares: 7568981.00
NERV income_statement (quarterly, 2025-03-31) — Basic EPS: -0.50
NERV cash_flow (quarterly, 2025-03-31) — Beginning Cash Position: 21462008.00
NERV balance_sheet (quarterly, 2025-03-31) — Capital Stock: 699.00
NERV balance_sheet (quarterly, 2025-03-31) — Cash And Cash Equivalents: 17290048.00
NERV balance_sheet (quarterly, 2025-03-31) — Cash Cash Equivalents And Short Term Investments: 17290048.00
NERV cash_flow (quarterly, 2025-03-31) — Cash Flow From Continuing Financing Activities: 0.00
NERV cash_flow (quarterly, 2025-03-31) — Cash Flow From Continuing Investing Activities: 0.00
NERV cash_flow (quarterly, 2025-03-31) — Cash Flow From Continuing Operating Activities: -4071960.00
NERV cash_flow (quarterly, 2025-03-31) — Change In Account Payable: -967898.00
NERV cash_flow (quarterly, 2025-03-31) — Change In Accrued Expense: 78223.00
NERV cash_flow (quarterly, 2025-03-31) — Change In Payable: -967898.00
NERV cash_flow (quarterly, 2025-03-31) — Change In Payables And Accrued Expense: -889675.00
NERV cash_flow (quarterly, 2025-03-31) — Change In Prepaid Assets: 272097.00
NERV cash_flow (quarterly, 2025-03-31) — Change In Working Capital: -617578.00
NERV cash_flow (quarterly, 2025-03-31) — Changes In Cash: -4071960.00
NERV balance_sheet (quarterly, 2025-03-31) — Common Stock: 699.00
NERV balance_sheet (quarterly, 2025-03-31) — Common Stock Equity: -29148843.00
NERV balance_sheet (quarterly, 2025-03-31) — Current Accrued Expenses: 867828.00
NERV balance_sheet (quarterly, 2025-03-31) — Current Assets: 17924846.00
NERV balance_sheet (quarterly, 2025-03-31) — Current Liabilities: 1947169.00
NERV cash_flow (quarterly, 2025-03-31) — Depreciation: 1361.00
NERV cash_flow (quarterly, 2025-03-31) — Depreciation Amortization Depletion: 1361.00
NERV cash_flow (quarterly, 2025-03-31) — Depreciation And Amortization: 1361.00
NERV income_statement (quarterly, 2025-03-31) — Diluted Average Shares: 7568981.00
NERV income_statement (quarterly, 2025-03-31) — Diluted EPS: -0.50
NERV income_statement (quarterly, 2025-03-31) — Diluted NI Availto Com Stockholders: -3752972.00
NERV income_statement (quarterly, 2025-03-31) — EBIT: -3902884.00
NERV income_statement (quarterly, 2025-03-31) — EBITDA: -3901523.00
NERV cash_flow (quarterly, 2025-03-31) — End Cash Position: 17390048.00
NERV cash_flow (quarterly, 2025-03-31) — Financing Cash Flow: 0.00
NERV cash_flow (quarterly, 2025-03-31) — Free Cash Flow: -4071960.00
NERV income_statement (quarterly, 2025-03-31) — Gain On Sale Of Security: 149912.00
NERV income_statement (quarterly, 2025-03-31) — General And Administrative Expense: 2540446.00
NERV balance_sheet (quarterly, 2025-03-31) — Goodwill: 14869399.00
NERV balance_sheet (quarterly, 2025-03-31) — Goodwill And Other Intangible Assets: 14869399.00
NERV income_statement (quarterly, 2025-03-31) — Interest Expense: 0.00
NERV income_statement (quarterly, 2025-03-31) — Interest Expense Non Operating: 0.00
NERV balance_sheet (quarterly, 2025-03-31) — Invested Capital: -29148843.00
NERV cash_flow (quarterly, 2025-03-31) — Investing Cash Flow: 0.00
NERV income_statement (quarterly, 2025-03-31) — Net Income: -3752972.00
NERV income_statement (quarterly, 2025-03-31) — Net Income Common Stockholders: -3752972.00
NERV income_statement (quarterly, 2025-03-31) — Net Income Continuous Operations: -3752972.00
NERV income_statement (quarterly, 2025-03-31) — Net Income From Continuing And Discontinued Operation: -3752972.00
NERV income_statement (quarterly, 2025-03-31) — Net Income From Continuing Operation Net Minority Interest: -3752972.00
NERV cash_flow (quarterly, 2025-03-31) — Net Income From Continuing Operations: -3752972.00
NERV income_statement (quarterly, 2025-03-31) — Net Income Including Noncontrolling Interests: -3752972.00
NERV income_statement (quarterly, 2025-03-31) — Net Interest Income: 0.00
NERV cash_flow (quarterly, 2025-03-31) — Net Investment Purchase And Sale: 0.00
NERV income_statement (quarterly, 2025-03-31) — Net Non Operating Interest Income Expense: 0.00
NERV balance_sheet (quarterly, 2025-03-31) — Net PPE: 4081.00
NERV balance_sheet (quarterly, 2025-03-31) — Net Tangible Assets: -44018242.00
NERV income_statement (quarterly, 2025-03-31) — Normalized EBITDA: -4051435.00
NERV income_statement (quarterly, 2025-03-31) — Normalized Income: -3902884.00
NERV cash_flow (quarterly, 2025-03-31) — Operating Cash Flow: -4071960.00
NERV income_statement (quarterly, 2025-03-31) — Operating Income: -3902884.00
NERV income_statement (quarterly, 2025-03-31) — Operating Revenue: 0.00
NERV balance_sheet (quarterly, 2025-03-31) — Ordinary Shares Number: 6993406.00
NERV balance_sheet (quarterly, 2025-03-31) — Other Current Assets: 534798.00
NERV income_statement (quarterly, 2025-03-31) — Other Gand A: 2540446.00
NERV income_statement (quarterly, 2025-03-31) — Other Income Expense: 149912.00
NERV balance_sheet (quarterly, 2025-03-31) — Other Non Current Liabilities: 60000000.00
NERV balance_sheet (quarterly, 2025-03-31) — Payables: 639946.00
NERV balance_sheet (quarterly, 2025-03-31) — Payables And Accrued Expenses: 1507774.00
NERV balance_sheet (quarterly, 2025-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 439395.00
NERV balance_sheet (quarterly, 2025-03-31) — Preferred Stock: 0.00
NERV income_statement (quarterly, 2025-03-31) — Pretax Income: -3752972.00
NERV cash_flow (quarterly, 2025-03-31) — Proceeds From Stock Option Exercised: 0.00
NERV cash_flow (quarterly, 2025-03-31) — Purchase Of Investment: 0.00
NERV income_statement (quarterly, 2025-03-31) — Reconciled Depreciation: 1361.00
NERV income_statement (quarterly, 2025-03-31) — Research And Development: 1362438.00
NERV balance_sheet (quarterly, 2025-03-31) — Restricted Cash: 100000.00
NERV balance_sheet (quarterly, 2025-03-31) — Retained Earnings: -399129535.00
NERV income_statement (quarterly, 2025-03-31) — Selling General And Administration: 2540446.00
NERV balance_sheet (quarterly, 2025-03-31) — Share Issued: 6993406.00
NERV cash_flow (quarterly, 2025-03-31) — Stock Based Compensation: 297229.00
NERV balance_sheet (quarterly, 2025-03-31) — Stockholders Equity: -29148843.00
NERV balance_sheet (quarterly, 2025-03-31) — Tangible Book Value: -44018242.00
NERV income_statement (quarterly, 2025-03-31) — Tax Effect Of Unusual Items: 0.00
NERV income_statement (quarterly, 2025-03-31) — Tax Rate For Calcs: 0.00